Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26,019,256
-
Total 13F shares
-
6,472,867
-
Share change
-
-267,940
-
Total reported value
-
$6,154,436
-
Price per share
-
$0.95
-
Number of holders
-
21
-
Value change
-
-$431,783
-
Number of buys
-
8
-
Number of sells
-
10
Institutional Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q4 2024
As of 31 Dec 2024,
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,472,867 shares.
The largest 10 holders included
Redmile Group, LLC, Sanofi, Merck & Co., Inc., Bruce & Co., Inc., SPHERA FUNDS MANAGEMENT LTD., Pathway Financial Advisors LLC, PNC Financial Services Group, Inc., TWO SIGMA INVESTMENTS, LP, BNP PARIBAS FINANCIAL MARKETS, and Engineers Gate Manager LP.
This page lists
21
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.